CorVista Health, ATSS to Provide Cardiovascular Diagnostic Platform in Middle East

CorVista Health Inc. has signed a Memorandum of Understanding (MOU) with Advanced Telecommunications Solutions and Services (ATSS) to explore the possibility of introducing the CorVista System into Saudi Arabia. The CorVista System is the world’s first point-of-care system for evaluating the presence of significant coronary artery disease (CAD) and pulmonary hypertension (PH) in a single visit.

“Collaborating with ATSS represents an opportunity to improve the standard of cardiovascular diagnostics in Saudi Arabia by generating reliable, actionable results faster than conventional tests and empowering cardiologists and pulmonologists to choose the right treatment path for their symptomatic patients at the initial examination, avoiding delay and invasive procedures,” CorVista Health President/CEO Don Crawford said. “This collaboration is part of CorVista Health’s efforts to expand global reach and support the growing need for innovative cardiovascular diagnostics in one of the world’s most dynamic healthcare markets.”

Cardiovascular diseases (CVD) are a leading cause of death globally, creating a growing healthcare burden in developed and emerging markets. These conditions, including CAD, account for more than 45% of all deaths in Saudi Arabia. By 2035, the economic burden of CVD within the Kingdom of Saudi Arabia is estimated to triple to more than $9.8 billion annually.¹

“We are look forward to partnering with CorVista Health to bring the CorVista System to Saudi Arabia. This reflects our mission to provide cutting-edge healthcare solutions that enhance patient care, streamline operations, and empower healthcare professionals with the tools they need to deliver exceptional service,” ATSS CEO Eng. Abdullah Alosaimi stated. “ATSS is a leading company across various sectors of digital transformation, including telemedicine, dedicated to supporting the Kingdom’s Vision 2030. This vision aligns with our commitment to bring the highest standard of healthcare to Saudi citizens and residents of Saudi Arabia. Through innovative collaborations such as our partnership with CorVista Health, we aim to deliver state-of-the-art cardiovascular diagnostics to the Kingdom, empowering healthcare professionals and improving patient outcomes across the region.”

CorVista System is a prescription-only, non-invasive point-of-care solution intended to synchronously collect and apply machine learning to a symptomatic patient’s cardiac and hemodynamic signals to predict the likelihood of cardiovascular diseases without the use of radiation, contrast agents, injections, fasting, or exercise. Within minutes of the test, the CorVista Analysis is available in a secure web portal to help physicians diagnose patients with suspected cardiovascular disease and answer important clinical questions to guide better treatment decisions. The CorVista System with CAD and PH Add-Ons has been cleared by the U.S. Food and Drug Administration. CorVista System is developed and manufactured by Analytics for Life Inc. and licensed to CorVista Health Inc.

CorVista Health Inc. offers the CorVista System platform to transform cardiovascular care and patient experience. CorVista Health is dedicated to enabling more equitable care by providing access to immediately actionable, high-quality cardiovascular status results in low-resource settings where access to capital-intensive equipment and the qualified specialists needed to operate them may not be available.

Reference
¹ J Saudi Heart Assoc. 2023 Jun 10;35(2):148–162. doi: 10.37616/2212-5043.1336